Zibotentan in Microvascular Angina: A Randomized, Placebo-Controlled, Crossover Trial.

ABSTRACT:

Background

Microvascular angina is associated with dysregulation of the endothelin system and impairments in myocardial blood flow, exercise capacity, and health-related quality of life. The G allele of the noncoding single nucleotide polymorphism RS9349379 enhances expression of the endothelin-1 gene (EDN1) in human vascular cells, potentially increasing circulating concentrations of Endothelin-1 (ET-1). Whether zibotentan, an oral ET-A receptor selective antagonist, is efficacious and safe for the treatment of microvascular angina is unknown.

Methods

Patients with microvascular angina were enrolled in this double-blind, placebo-controlled, sequential crossover trial of zibotentan (10 mg daily for 12 weeks). The trial population was enriched to ensure a

SUBMITTER: Morrow A 

PROVIDER: S-EPMC11573082 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature